Evotec SE (NASDAQ:EVO) Short Interest Update

Evotec SE (NASDAQ:EVO) was the target of a large decline in short interest in October. As of October 31st, there was short interest totalling 220,100 shares, a decline of 10.7% from the October 15th total of 246,500 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 138,900 shares, the short-interest ratio is presently 1.6 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Evotec during the 2nd quarter valued at about $87,000. Clear Harbor Asset Management LLC acquired a new position in shares of Evotec during the 3rd quarter valued at about $104,000. Cetera Advisors LLC acquired a new position in shares of Evotec during the 1st quarter valued at about $188,000. Mediolanum International Funds Ltd acquired a new position in shares of Evotec during the 3rd quarter valued at about $512,000. Finally, DCF Advisers LLC increased its position in Evotec by 140.5% during the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock worth $552,000 after purchasing an additional 67,156 shares in the last quarter. Institutional investors and hedge funds own 5.81% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on EVO shares. Deutsche Bank Aktiengesellschaft lowered shares of Evotec from a “hold” rating to a “sell” rating in a research report on Thursday, August 8th. Jefferies Financial Group lowered shares of Evotec from a “buy” rating to a “hold” rating and reduced their target price for the company from $8.70 to $3.80 in a report on Monday, October 7th. Morgan Stanley lowered shares of Evotec from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $15.00 to $6.00 in a report on Monday, July 29th. Finally, HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Evotec in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $5.93.

Evotec Stock Up 2.0 %

NASDAQ:EVO traded up $0.11 on Monday, reaching $5.55. The stock had a trading volume of 281,458 shares, compared to its average volume of 130,829. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99. The firm’s fifty day moving average is $3.66 and its two-hundred day moving average is $4.19. Evotec has a 12-month low of $2.85 and a 12-month high of $12.00.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.